144 related articles for article (PubMed ID: 29627320)
41. Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1.
Jiang X; Shen X
Bull Cancer; 2018 Oct; 105(10):873-883. PubMed ID: 30266288
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
Huang XP; Hou J; Shen XY; Huang CY; Zhang XH; Xie YA; Luo XL
FEBS J; 2015 Feb; 282(3):579-94. PubMed ID: 25475121
[TBL] [Abstract][Full Text] [Related]
43. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.
Leung CO; Wong CC; Fan DN; Kai AK; Tung EK; Xu IM; Ng IO; Lo RC
Oncotarget; 2015 May; 6(13):10880-92. PubMed ID: 25834102
[TBL] [Abstract][Full Text] [Related]
44. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.
Wang F; Ying HQ; He BS; Pan YQ; Deng QW; Sun HL; Chen J; Liu X; Wang SK
Oncotarget; 2015 Apr; 6(10):7899-917. PubMed ID: 25760077
[TBL] [Abstract][Full Text] [Related]
45. Long noncoding RNA AFAP1-AS1 indicates a poor prognosis of hepatocellular carcinoma and promotes cell proliferation and invasion via upregulation of the RhoA/Rac2 signaling.
Zhang JY; Weng MZ; Song FB; Xu YG; Liu Q; Wu JY; Qin J; Jin T; Xu JM
Int J Oncol; 2016 Apr; 48(4):1590-8. PubMed ID: 26892468
[TBL] [Abstract][Full Text] [Related]
46. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.
Li H; Miao Q; Xu CW; Huang JH; Zhou YF; Wu MJ
J Korean Med Sci; 2016 Aug; 31(8):1215-23. PubMed ID: 27478331
[TBL] [Abstract][Full Text] [Related]
47. Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway.
Wang X; Zhang J; Zhou L; Sun W; Zheng ZG; Lu P; Gao Y; Yang XS; Zhang ZC; Tao KS; Dou KF
Int J Oncol; 2015 Jul; 47(1):231-43. PubMed ID: 25955618
[TBL] [Abstract][Full Text] [Related]
48. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.
Niwa Y; Kanda H; Shikauchi Y; Saiura A; Matsubara K; Kitagawa T; Yamamoto J; Kubo T; Yoshikawa H
Oncogene; 2005 Sep; 24(42):6406-17. PubMed ID: 16007195
[TBL] [Abstract][Full Text] [Related]
49. MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3.
Wang Z; Yang H; Ren L
Biochem Biophys Res Commun; 2015 Sep; 464(4):1228-1234. PubMed ID: 26210448
[TBL] [Abstract][Full Text] [Related]
50. Upregulation of LncDQ is Associated with Poor Prognosis and Promotes Tumor Progression via Epigenetic Regulation of the EMT Pathway in HCC.
Zeng B; Lin Z; Ye H; Cheng D; Zhang G; Zhou J; Huang Z; Wang M; Cai C; Zeng J; Tang C; Liu J
Cell Physiol Biochem; 2018; 46(3):1122-1133. PubMed ID: 29669339
[TBL] [Abstract][Full Text] [Related]
51. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway.
Ma X; Qiu Y; Sun Y; Zhu L; Zhao Y; Li T; Lin Y; Ma D; Qin Z; Sun C; Han L
Cell Death Dis; 2020 Mar; 11(3):174. PubMed ID: 32144252
[TBL] [Abstract][Full Text] [Related]
52. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of protein O-fucosyltransferase 1 accelerates hepatocellular carcinoma progression via the Notch signaling pathway.
Ma L; Dong P; Liu L; Gao Q; Duan M; Zhang S; Chen S; Xue R; Wang X
Biochem Biophys Res Commun; 2016 Apr; 473(2):503-10. PubMed ID: 27003260
[TBL] [Abstract][Full Text] [Related]
54. A FUS-LATS1/2 Axis Inhibits Hepatocellular Carcinoma Progression via Activating Hippo Pathway.
Bao L; Yuan L; Li P; Bu Q; Guo A; Zhang H; Cui N; Liu B
Cell Physiol Biochem; 2018; 50(2):437-451. PubMed ID: 30308519
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-150 suppresses cell proliferation and metastasis in hepatocellular carcinoma by inhibiting the GAB1-ERK axis.
Sun W; Zhang Z; Wang J; Shang R; Zhou L; Wang X; Duan J; Ruan B; Gao Y; Dai B; Qu S; Liu W; Ding R; Wang L; Wang D; Dou K
Oncotarget; 2016 Mar; 7(10):11595-608. PubMed ID: 26871477
[TBL] [Abstract][Full Text] [Related]
56. Stachydrine hydrochloride inhibits hepatocellular carcinoma progression via LIF/AMPK axis.
Bao X; Liu Y; Huang J; Yin S; Sheng H; Han X; Chen Q; Wang T; Chen S; Qiu Y; Zhang C; Yu H
Phytomedicine; 2022 Jun; 100():154066. PubMed ID: 35366490
[TBL] [Abstract][Full Text] [Related]
57. AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation.
Ferretti AC; Tonucci FM; Hidalgo F; Almada E; Larocca MC; Favre C
Oncotarget; 2016 Apr; 7(14):17815-28. PubMed ID: 26894973
[TBL] [Abstract][Full Text] [Related]
58. Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma.
Lv X; Zhao F; Huo X; Tang W; Hu B; Gong X; Yang J; Shen Q; Qin W
Med Oncol; 2016 Jul; 33(7):70. PubMed ID: 27262566
[TBL] [Abstract][Full Text] [Related]
59. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer.
Chen WC; Chang YS; Hsu HP; Yen MC; Huang HL; Cho CY; Wang CY; Weng TY; Lai PT; Chen CS; Lin YJ; Lai MD
Oncotarget; 2015 Dec; 6(40):42923-37. PubMed ID: 26556861
[TBL] [Abstract][Full Text] [Related]
60. Overexpression of OCT4 contributes to progression of hepatocellular carcinoma.
Xu G; Qi F; Zhang J; Xu J; Shi T; Miao Y
Tumour Biol; 2016 Apr; 37(4):4649-54. PubMed ID: 26508029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
